News and Event
15631
page-template-default,page,page-id-15631,page-child,parent-pageid-16382,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

News and Event

October 22, 2019 / New and Event

A first-in-human study of Tenalisib in patients wi...

Glad to share the publication of the manuscript "A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in...
Read More
September 28, 2019

Approval For Phase III study of New Antibiotics...

Excited to share news that a study that we designed and presented to the Subject Expert Committee (SEC), received clearance...
Read More
September 7, 2019

Clinical Study Report (CSR)...

Excited to share the news that Med Indite Communications recently completed a CSR of an integrated Phase I study involving...
Read More
August 25, 2019

Tissue Agnostic Therapy...

My recent article on Tissue Agnostic Therapy. https://www.linkedin.com/pulse/tissue-agnostic-therapy-dr-mohini-barde-md/?trackingId=0RB2SlBtzw0ArQ7gOq67Rw%3D%3D  
Read More
April 20, 2019

Visit to Tata Memorial Hospital...

Today, visited to Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer with Dr. Michael Wargovich, Professor,...
Read More
September 29, 2018

Deliberation on the study Design...

Today, discussed and debated the most appropriate study design for Negative-Pressure Wound therapy (NPWT) with Cam Hutton, CEO of Healyx...
Read More
1 2